Abstract: The segments of an anatomically corresponding bull's eye graph familiar to echocardiologists is annotated by coloring those segments for which ECG data indicates the presence of myocardial infarction injury. In an illustrated example, segments are colored with a second color when the ECG data corresponding to those segments are indicated as being the site of a coronary occlusion. The segments of the bull's eye graph may be colored in a third color with the results of a diagnostic imaging exam, such as by coloring segments exhibiting wall motion abnormalities with a third color.

Abstract: A diagnostic ECG system analyzes lead traces for evidence of ST elevation in the lead signals. The pattern of ST elevation in leads having predetermined vantage points to the electrical activity of the heart and, in some instances, the presence of ST depression in certain other leads, identifies a specific coronary artery or branch as the culprit coronary artery for an acute ischemic event. The identity of the culprit coronary artery or branch is presented to the interventional cardiologist so that the correct coronary artery is accessed and the obstruction cleared. The technique can be used with standard 12-lead ECG systems as well as with ECG systems using fewer or more leads.

Abstract: A diagnostic ECG system analyzes lead traces for evidence of ST elevation in the lead signals. The pattern of ST elevation in leads having predetermined vantage points to the electrical activity of the heart and, in some instances, the presence of ST depression in certain other leads, identifies a specific coronary artery or branch as the culprit coronary artery for an acute ischemic event. The identity of the culprit coronary artery or branch is presented to the interventional cardiologist so that the correct coronary artery is accessed and the obstruction cleared. The technique can be used with standard 12-lead ECG systems as well as with ECG systems using fewer or more leads.

Abstract: An atrial fibrillation (AF) monitor extracts two P wave features and an R-R interval feature from a sequence of ECG waveforms. The features are used by a classifier to classify a heart rhythm as AF or non-AF. The AF classification results may be further processed to reduce false alarm reporting. The AF classification results are used by an AF burden calculator to report AF burden in real time.

Abstract: An ECG monitoring system continuously monitors a patient's ECG waveform and periodically identifies the patient's QT interval. QT interval values are averaged over time and a corrected interval value QTc and a change in QTc relative to a baseline, dQTc, are periodically produced. An alarm is responsive to updated QT interval values and issues an alarm whenever a selected QT value exceeds an alarm limit. The periodically produced QT interval values are stored and a trend display may be produced showing changes in the QT interval information over different periods of time. The trend display may selectively display the trend information either graphically or in tabular form.

Abstract: A physiological parameter analysis system (10) detects ECG electrode wire misplacement. The system (10) includes a transformation component (32) that transforms original ECG information and combinations thereof from a first ECG lead system to a second ECG lead system and an inverse transformation component (34) that derives ECG information in the first ECG lead system from the transformed ECG information and the combinations thereof. The system (10) further includes an analysis component (38) that determines a correct ECG lead configuration in the first ECG lead system from among the original ECG information and the combinations thereof based on the derived ECG information.

Abstract: A physiological parameter analysis system (10) detects ECG electrode wire misplacement. The system (10) includes a transformation component (32) that transforms original ECG information and combinations thereof from a first ECG lead system to a second ECG lead system and an inverse transformation component (34) that derives ECG information in the first ECG lead system from the transformed ECG information and the combinations thereof. The system (10) further includes an analysis component (38) that determines a correct ECG lead configuration in the first ECG lead system from among the original ECG information and the combinations thereof based on the derived ECG information.

Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.

Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.

Abstract: A method is provided for inhibiting or treating diseases associated with acid lipase deficiency by administering to a patient an MTP inhibitor, alone or optionally, in combination with another cholesterol lowering drug, such as pravastatin.

Abstract: A method is provided for inhibiting onset of or treating phytosterolemia by administering to a patient an MTP inhibitor, alone or optionally, in combination with another cholesterol lowering drug, such as pravastatin.

Abstract: A method is provided for lowering serum lipids, cholesterol and/or triglycerides and thereby inhibiting atherosclerosis by administering to a patient an MTP inhibitor, in combination with a cholesterol lowering drug, such as pravastatin.

Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.

Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.

Abstract: A single line clamshell bucket apparatus having new and improved guided amatic latching means for effecting positive operation while raising, lowering and operating the bucket apparatus for picking up and dumping a load.